生物疫苗板塊走強 國家藥監局:急需疫苗可免予批簽發
格隆匯12月22日丨生物疫苗板塊拉昇走強,西藏藥業漲超5%,復星醫藥漲近4%,華蘭生物、康希諾-U、智飛生物、沃森生物等紛紛上揚。近日,英國出現新冠病毒新變種毒株,其傳播能力比原始毒株高70%。鍾南山院士表示,英國病毒變異對疫苗影響尚無證據。張文宏更新微博表示,英國突變株並不意外,疫苗接種有條不紊推進即可。國家藥監局12月21日晚間披露,其起草修訂後的《生物製品批簽發管理辦法》將自2021年3月1日起實施。考慮到目前我國疫苗產業發展迅速、未來疫苗出口可能持續增加的現狀,今後我國應對突發事件急需的疫苗,經國家藥監局批准即可免予批簽發。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.